Document:

EX-4.12

 Exhibit 4.12 

THIS CONVERTIBLE PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN
COMPLIANCE WITH RULE 144 UNDER SAID ACT OR AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL FOR THE HOLDER, SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT OR RECEIPT OF A NO-ACTION LETTER FROM THE SECURITIES AND EXCHANGE COMMISSION. 
 CONVERTIBLE PROMISSORY NOTE

  

					
	$2,000,000.00	  	 	November 19, 2012	  

 For value received GENO, LLC, a Delaware limited liability company, with offices at 2941
Oxbow Circle, Cocoa, Florida 32926 (“Borrower”), hereby unconditionally promises to pay, in lawful money of the United States of America, to The Medicines Company, a Delaware corporation, with offices at 8 Sylvan Way,
Parsippany, New Jersey 07054, or its assigns (“Lender”), the principal sum of Two Million ($2,000,000.00) Dollars, together with accrued and unpaid interest thereon, each due and payable on the dates and in the manner set
forth below. 
 1. Repayment and Conversion.  

(a) Unless this Convertible Promissory Note (this “Note”) has been converted in accordance with the terms of
this Section 1, the entire outstanding principal balance and all accrued and unpaid interest shall become fully due and payable on November 19, 2013 (the “Maturity Date”). 

(b) In the event that Borrower issues and sells, or the Borrower enters into, agrees to or approves of the issuance or sale of, shares
of its Equity Securities (defined below) to one or more entities or individuals (the “Investors”) on or before the Maturity Date in a financing with total proceeds to the Borrower of not less than $10,000,000 (excluding the
conversion of any outstanding indebtedness and this Note) (a “Qualified Financing”), then the outstanding principal balance of this Note and all outstanding and unpaid interest may, at the election (in writing) of Lender (the
“Lender Election”), automatically convert in whole without any further action by the Lender, other than (i) surrender of this Note to the Borrower for cancellation and (ii) execution of customary agreements (such as
voting agreements) required by the Investors in the Qualified Financing on or before the Qualified Financing Deadline (defined below), into the Equity Securities sold in the Qualified Financing at a conversion price equal to the price per share paid
by the Investors purchasing the Equity Securities in the Qualified Financing. The Borrower shall provide the Lender with at least ten (10) business days’ written notice of the initial closing of a Qualified Financing, along with the
documents to be entered into by the Investors in connection therewith. If the Lender does not deliver this Note, duly endorsed for cancellation in exchange for Equity Securities, along with signature pages to the agreements required by the Investors
described in the previous sentence, on or before the Qualified Financing Deadline, then this Note shall no longer be convertible into equity securities of the 

 
Borrower at the sole discretion of the Lender and the Borrower shall have the right to pay the Lender, on or before the Maturity Date, the outstanding principal balance of this Note and all
outstanding and unpaid interest in full satisfaction of the Borrower’s obligations hereunder. For purposes of this Note, the term “Equity Securities” shall mean the Borrower’s Common Shares (as such term is defined
in the Seventh Amended and Restated Limited Liability Company Agreement of the Borrower, dated as of April 1, 2010, as the same may be amended from time to time (the “Operating Agreement”)) or any equity securities with
rights and preferences senior to the Borrower’s Common Shares; and “Qualified Financing Deadline” shall mean the date of the initial closing of the Qualified Financing. 

(c) At any time on or after the Maturity Date, if all principal and interest outstanding under this Note have not been paid in full,
then the Lender may either (i) demand payment of the entire outstanding principal balance of this Note and all outstanding principal and unpaid accrued interest (a “Payment Demand”) or (ii) convert the entire
outstanding principal balance of this Note and all unpaid accrued interest into shares of the Borrower’s Common Shares at a conversion price equal to $5.25 per share. 

(d) In the event that, prior to a Qualified Financing, (A) either (i) the Borrower enters into or approves a written
acquisition agreement for (a) a sale, lease or other disposition of all or substantially all of its assets, or (b) a consolidation or merger of the Borrower with or into any other corporation or other entity or person, or any other
corporate reorganization in which the stockholders of the Borrower immediately prior to such consolidation, merger or reorganization own less than 50% of the voting power of the surviving entity immediately after such consolidation, merger or
reorganization of the Borrower, or (ii) the Borrower otherwise has knowledge that the stockholders of the Borrower expect to enter into, within 30 days, a written agreement for a transaction not included in (i) above for the sale of
outstanding shares of the Borrower and the shareholders of the Borrower immediately prior to such transaction will own less than 50% of the voting power of the Borrower immediately after such transaction (including a transaction described in this
Subsection (A) that also includes a Qualified Financing), (B) this Note has not been paid in full or converted into capital stock of the Borrower, and (C) a transaction described in (A) above is consummated, then, before any
distribution or payment shall be made to the holders of equity securities of the Borrower in connection with such transaction, the Borrower shall pay the Lender $2,500,000 in full satisfaction of the Borrower’s obligations under this Note. 

(e) Common Shares issued to the Lender on conversion under Sections 1(c) or 8 shall be deemed to have been issued pursuant to the Fourth Share
Subscription (as defined in the Operating Agreement) or shall otherwise have economic rights and preferences commensurate with (but not voting or control rights commensurate with) Borrower’s most senior class of issued equity as of the time of
conversion. 
 2. Mechanics of Conversion. In the event that the Lender converts this Note pursuant to Sections 1(c) or 8, the Lender
shall surrender this Note, at the office of the Borrower or any transfer agent for the securities into which this Note converts (the “Conversion Shares”). Such conversion shall be deemed to have been made at the close of
business on the date this Note is surrendered, and the person entitled to receive the Conversion Shares shall be treated for all purposes as the record holder of such Conversion Shares on such date. 

  
 - 2 - 

 3. Fractional Shares. No fractional share shall be issued upon the conversion of this
Note. All shares issuable upon conversion of the outstanding amount of this Note shall be aggregated for purposes of determining whether the conversion would result in the issuance of any fractional share. If, after the aforementioned aggregation,
the conversion would result in the issuance of a fraction of a share, Borrower shall, in lieu of issuing any fractional share, pay Lender who is otherwise entitled to such fraction a sum in cash equal to the fair market value of such fraction on the
date of conversion (as determined in good faith by the Borrower’s Board of Managers).  
 4. Interest. Unpaid principal
of this Note shall bear interest (computed on the basis of a year of 365 days of actual days elapsed), from the date hereof until such principal is paid, at a rate per annum which shall be equal to six and one-quarter percent (6.25%). 

5. Prepayment. At any time prior to the Maturity Date, other than as set forth in Sections 1(b) and 1(d) (which shall not require
the Lender’s consent), Borrower may pay this Note, in whole or in part, after first obtaining the written consent of the Lender, which consent shall not be unreasonably withheld.  

6. Place of Payment. All amounts payable hereunder shall be payable at the office of Lender at 8 Sylvan Way, Parsippany, New Jersey
07054, unless another place of payment shall be specified in writing by Lender. 
 7. Default. Each of the following events shall be
an “Event of Default” hereunder: 
 (a) Borrower fails to pay, within five (5) business days of a
Payment Demand by Lender, any and all unpaid principal, accrued interest and other amounts owing hereunder; 
 (b) Borrower files any
petition or action for relief under any bankruptcy, reorganization, insolvency or moratorium law or any other law for the relief of, or relating to, debtors, now or hereafter in effect, or makes any assignment for the benefit of creditors or takes
any corporate action in furtherance of any of the foregoing; or 
 (c) An involuntary petition is filed against Borrower (unless such
petition is dismissed or discharged within 60 days) under any bankruptcy statute now or hereafter in effect, or a custodian, receiver, trustee, assignee for the benefit of creditors (or other similar official) is appointed to take possession,
custody or control of any property of Borrower. 
 8. Remedies. Upon the occurrence of any Event of Default, all unpaid principal on
this Note, accrued and unpaid interest thereon and all other amounts owing hereunder shall automatically be immediately due, payable and collectible by Lender pursuant to applicable law, without presentment, demand, protest or notice. Upon
acceleration or maturity of this Note, interest on the unpaid principal shall accrue at an annual rate of ten (10%) percent. This interest rate shall survive the entry of any judgment relating to this Note. At any time after the

  
 - 3 - 

 
occurrence of an Event of Default, without advance notice to the Company but only upon surrender of this Note for cancellation, Lender may convert all amounts due under this Note
(including principal and interest) into Common Shares at a conversion price equal to $5.25 per share. 
 9. Accredited
Investor. Lender is an “accredited investor” within the meaning of Rule 501 of Regulation D promulgated under the Securities Act of 1933, as amended. 

10. Usury. In no event shall the interest rate or rates payable under this Note, plus any other amounts paid in
connection herewith and therewith, exceed the highest rate permissible under any law that a court of competent jurisdiction shall, in a final determination, deem applicable. Borrower and Lender, in executing and delivering this Note, intend legally
to agree upon the rate or rates of interest and manner of payment stated within it; provided, however, that, anything contained herein to the contrary notwithstanding, if said rate or rates of interest or manner of payment exceeds the
maximum allowable under applicable law, then, ipso facto, as of the date of this Note, Borrower is and shall be liable only for the payment of such maximum as allowed by law, and payment received from Borrower in excess of such legal maximum,
whenever received, shall be applied to reduce the principal balance of any remaining obligations to the extent of such excess. 

11. Borrower Representations. In connection with the execution of this Note, the Borrower represents to the Lender the following:

 (a) Organization, Standing and Qualification. The Borrower is a limited liability company that is duly organized, validly
existing, and in good standing under the laws of the State of Delaware and the Borrower has all necessary power and authority to own, lease and operate its properties and carry on its business as now operated and as proposed to be operated. The
Borrower is duly qualified to do business and is in good standing in all jurisdictions in which failure to so qualify would have a materially adverse effect upon the operations, financial condition and prospects of such entity. 

(b) Power and Authorization. The Borrower has all requisite limited liability company power to execute and deliver this Note and to
carry out and perform its obligations under the terms of this Note. All limited liability company action on the part of the Borrower, its members and/or managers necessary for the authorization, execution and performance of this Note by the Borrower
and the performance of the Borrower’s obligations hereunder has been taken or will be taken prior to the execution of this Note. This Note, when executed and delivered by the Borrower, shall constitute valid and binding obligations of the
Borrower enforceable in accordance with its terms, subject to laws of general application relating to bankruptcy, insolvency, the relief of debtors and, with respect to rights to indemnity, subject to federal and state securities laws. 

(c) Consents. All consents, approvals, orders or authorizations of, or registrations, qualifications, designations, declarations or
filings with, any third parties or governmental authority, required on the part of the Borrower in connection with the valid execution and delivery of this Note or the consummation of any other transaction contemplated

  
 - 4 - 

 
hereby shall have been obtained or will be obtained prior to the execution of this Note, except for notices required or permitted to be filed with certain state and federal securities
commissions, which notices will be filed on a timely basis. 
 (d) Offering Valid. Assuming the accuracy of the representations and
warranties of the Borrower hereof, the offer, sale and issuance of any new shares of the Borrower’s capital stock upon conversion of this Note will be exempt from registration requirements of the Securities Act of 1933, as amended, and will
have been registered or qualified (or are exempt from registration and qualification) under the registration, permit or qualification requirements of all applicable state securities laws. 

(e) Conversion Shares. The shares of the Borrower’s capital stock, when issued in compliance with the provisions of this Note,
will be validly issued, fully paid and nonassessable and free of any liens or encumbrance, other than any restrictions on transfer under state and/or federal securities laws as set forth herein or as otherwise required by such laws at the time a
conversion is proposed. 
 (f) Priority. This Note, the indebtedness evidenced by this Note and all payments or rights under this
Note are senior to all indebtedness or other monetary obligations of the Borrower outstanding as of the date of this Note. David Fine, on behalf of himself and entities controlled by him, will execute a reasonable and customary subordination
agreement in order to evidence Lender’s senior rights under this Note. 
 13. Governing Law. This Note shall be governed by, and
construed and enforced in accordance with, the laws of the State of New York, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction. 

14. Expenses and Attorneys’ Fees. The Borrower shall indemnify and hold the Lender harmless from any loss, cost, liability and
legal or other expense, including attorneys’ fees of Lender’s counsel, which Lender may directly or indirectly suffer or incur by reason of the failure of the Borrower to perform any of its obligations under this Note. 

15. Amendment. This Note may be amended with the written consent of Borrower and Lender. 

16. Waiver of Jury Trial. TO THE EXTENT EACH MAY LEGALLY DO SO, EACH PARTY HERETO HEREBY EXPRESSLY WAIVES ANY RIGHT TO TRIAL BY JURY OF
ANY CLAIM, DEMAND, ACTION, CAUSE OF ACTION, OR PROCEEDINGS ARISING UNDER OR WITH RESPECT TO THIS NOTE, OR IN ANY WAY CONNECTED WITH, OR RELATED TO, OR INCIDENTAL TO, THE DEALING OF THE PARTIES HERETO WITH RESPECT TO THIS NOTE, IN EACH CASE WHETHER
NOW EXISTING OR HEREAFTER ARISING, AND IRRESPECTIVE OF WHETHER SOUNDING IN CONTRACT, TORT, OR OTHERWISE. TO THE EXTENT EACH MAY LEGALLY DO SO, EACH PARTY HERETO HEREBY AGREES THAT ANY SUCH CLAIM, DEMAND, ACTION, OR PROCEEDING SHALL BE DECIDED BY A
COURT TRIAL WITHOUT A JURY AND THAT EITHER PARTY HERETO MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS NOTE WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF ANY OTHER PARTY HERETO TO THE WAIVER OF ITS RIGHT TO TRIAL BY JURY. 

  
 - 5 - 

 17. Successors and Assigns. The provisions of this Note shall inure to the benefit of and
be binding on any successor to Borrower and shall extend to any holder hereof. 
 18. Notices. All notices, demands, and other
communications provided for or permitted hereunder shall be made in writing and shall be by personal delivery, courier service, registered or certified first-class mail, return receipt requested, or telecopier to the addresses set forth below. All
such notices, demands and communications shall be deemed to have been duly given (a) when delivered by hand, if personally delivered; (b) when delivered by courier, if delivered by commercial overnight courier service; (c) if mailed,
five (5) business days after being deposited in the mail, postage prepaid; or (d) if telecopied, when transmission is confirmed.  

The Borrower: 

GeNO, LLC 
 2941 Oxbow Circle 

Cocoa, FL 32926 
 Telecopier No.:
(321) 784-6214 
 Attention: President 

With a copy (which shall not constitute notice) to: 

Choate, Hall & Stewart LLP 

Two International Place 
 Boston,
MA 02110 
 Attention: Brian D. Goldstein 

Facsimile No.: (617) 502-5110 

The Lender: 
 The
Medicines Company 
 8 Sylvan Way 

Parsippany, NJ 07054 
 Attention:
Chief Financial Officer 
 Telecopier No: (862) 264-1436 

  
 - 6 - 

 With a copy (which shall not constitute notice) to: 

The Medicines Company 
 8 Sylvan
Way 
 Parsippany, NJ 07054 

Attention: General Counsel 

Telecopier No: (862) 207-6062 

and 
 Gibbons P.C. 

One Gateway Center 
 Newark, NJ
07102 
 Attention: David E. De Lorenzi, Esq. 

Telecopier No.: (973) 639-6235 

[Signature Pages to Follow] 

  
 - 7 - 

 IN WITNESS WHEREOF, the Borrower has caused this Note to be duly executed on the date
first set forth above. 
  

			
	BORROWER:
	
	GENO, LLC
		
	By:	 	 /s/ David H. Fine

	Name:	 	David Fine
	Title:	 	President
	
	LENDER:
	
	THE MEDICINES COMPANY
		
	By:	 	 /s/ Glenn Sblendorio

	Name:	 	Glenn Sblendorio
	Title:	 	President & CFOEX-4.14

 Exhibit 4.14 

THIS WARRANT AND THE COMMON SHARES WHICH MAY BE PURCHASED UPON THE EXERCISE OF THIS WARRANT HAVE BEEN ACQUIRED SOLELY FOR INVESTMENT AND HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF SUCH REGISTRATION OR AN OPINION OF COUNSEL
REASONABLY SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH SALE, OFFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF THE ACT AND OF ANY APPLICABLE STATE SECURITIES LAWS. 

GENO LLC 
 COMMON SHARES WARRANT

  

			
	CS-1	  	 Issued as of November 29, 2011

Void after the Expiration Date

 WARRANT TO PURCHASE COMMON SHARES 

For value received, GeNO LLC, a Delaware limited liability company (the “Company”), hereby certifies that The Medicines
Company, a Delaware corporation (the “Holder”), subject to the provisions and upon the terms and conditions hereinafter set forth, is entitled to subscribe for and purchase from the Company, at any time after the Transaction
Termination Event (as defined below) before the Expiration Date (as defined below), up to 951,777 Common Shares of the Company (the “Shares”). This Warrant is issued by the Company pursuant to a Securities Purchase Agreement, of
even date herewith, by and between the Company and MDCO (the “Securities Purchase Agreement”). Unless otherwise defined herein, defined terms used in this Warrant will have the same meanings as are ascribed to them in the Securities
Purchase Agreement. 
 1. Definitions. As used in this Warrant: 

“Company Operating Agreement” means that certain Seventh Amended and Restated Limited Liability Company
Agreement of the Company, dated as of April 1, 2010, as amended by Amendment No. 1, dated as of January 1, 2011, as the same may be amended from time to time. 

“Exercise Price” means $7.88 per Share. 

“Expiration Date” means the earlier of (a) a Liquidation Event, (b) the closing of an IPO or
(c) September 30, 2016. 
 “IPO” means the Company’s initial underwritten offering and sale
of its shares to the public pursuant to an effective registration statement under the Securities Act. 

 “Liquidation Event” shall have the meaning ascribed to it in the
Company Operating Agreement. 
 “Person” means an individual, firm, corporation, partnership, association,
limited liability company, trust, governmental entity or any other entity. 
 “Rights Agreement” means that
certain Investor Rights Agreement, of even date herewith, by and between the Company and MDCO. 
 “Securities
Act” means the Securities Act of 1933, as amended. 
 “Transaction Termination Event” means the
later of the Option Termination Event and the Matching Right Termination Event (as those terms are defined in the Rights Agreement). 
 2.
Method of Exercise and Payment; Conditions to Exercise. 
 (a) Method of Exercise and Payment. The purchase rights represented
by this Warrant may be exercised by MDCO, in whole or in part, by the surrender of this Warrant (with the notice of exercise form attached hereto as Exhibit A duly executed) at the principal office of the Company, and by the payment to
the Company, by wire transfer of immediately available funds, of an amount equal to the aggregate Exercise Price of the Shares being purchased. 

(b) Conditions to Exercise. As a condition to the exercise of this Warrant (unless otherwise waived in writing by the Company), MDCO
shall reaffirm the representations and warranties as provided in Section 5 of this Warrant. 
 (c) Fractional Shares.
This Warrant may not be exercised for fractional shares. 
 3. Shares Fully Paid. All of the Shares issuable upon the exercise of the
rights represented by this Warrant will, upon issuance and receipt of the Exercise Price therefor, be fully paid and nonassessable, and free from all taxes, liens, claims, encumbrances and charges with respect to the issue thereof provided the
Shares are issued to the registered Holder. 
 4. Adjustment of Exercise Price and Number of Common Shares. The number and kind of
securities purchasable upon the exercise of this Warrant and the Exercise Price shall be subject to adjustment from time to time upon the occurrence of certain events, as follows: 

(a) Reclassification or Merger. In case of any reclassification or change of securities of the class issuable upon exercise of this
Warrant, or in case of any merger of the Company with or into another corporation (other than a merger with another entity in which the Company is the acquiring and the surviving entity and which does not result in any reclassification or change of
outstanding securities issuable upon exercise of this Warrant), or in case of any sale of all or substantially all of the assets of the Company, the Company, or such successor or purchasing corporation, as the case may be, shall duly execute and
deliver to the Holder a new Warrant (in form and substance satisfactory to the Holder), so that the Holder shall have the right to receive upon exercise of this Warrant, at a total purchase price not to exceed

  
 - 2 - 

 
that payable upon the exercise of the unexercised portion of this Warrant, and in lieu of the Common Shares theretofore issuable upon exercise of this Warrant, (i) the kind and amount of
units, shares of stock, other securities, money and property receivable upon such reclassification, change, merger or sale by a holder of the number of Common Shares then purchasable under this Warrant, or (ii) in the case of such a merger or
sale in which the consideration paid consists all or in part of assets other than securities of the successor or purchasing corporation or other legal entity, at the option of the Holder, the securities of the successor or purchasing corporation or
other legal entity having a value at the time of the transaction equivalent to the value of the Common Shares purchasable upon exercise of this Warrant at the time of the transaction. Any new Warrant shall provide for adjustments that shall be as
nearly equivalent as may be practicable to the adjustments provided for in this Section 4. The provisions of this Section 4 shall similarly apply to successive reclassifications, changes, mergers and sales. 

(b) Subdivision or Combination of Common Shares. If the Company at any time while this Warrant remains outstanding and unexpired shall
subdivide or combine its outstanding Common Shares, the Exercise Price shall be proportionately decreased and the number of Common Shares issuable hereunder shall be proportionately increased in the case of a subdivision and the Exercise Price shall
be proportionately increased and the number of Common Shares issuable hereunder shall be proportionately decreased in the case of a combination. 

(c) Dividends and Other Distributions. If the Company at any time while this Warrant is outstanding and unexpired shall pay a dividend
with respect to Common Shares payable in Common Shares, then the Exercise Price shall be adjusted, from and after the date of determination of unit holders entitled to receive such dividend or distribution, to that price determined by multiplying
the Exercise Price in effect immediately prior to such date of determination by a fraction (i) the numerator of which shall be the total number of Common Shares outstanding immediately prior to such dividend or distribution, and (ii) the
denominator of which shall be the total number of Common Shares outstanding immediately after such dividend or distribution. 
 (d)
Adjustment of Number of Common Shares. Upon each adjustment in the Exercise Price, the number of Common Shares purchasable hereunder shall be adjusted, to the nearest whole Common Share, to the product obtained by multiplying the number of
Common Shares purchasable immediately prior to such adjustment in the Exercise Price by a fraction, the numerator of which shall be the Exercise Price immediately prior to such adjustment and the denominator of which shall be the Exercise Price
immediately thereafter. 
 (e) Notice of Adjustment. Whenever the Exercise Price or the number of Common Shares purchasable hereunder
shall be adjusted pursuant to this Section 4, the Company shall make a certificate signed by its chief financial officer setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the method by
which such adjustment was calculated, and the Exercise Price and the number of Common Shares purchasable hereunder after giving effect to such adjustment, and shall cause copies of such certificate to be mailed to the Holder. 

  
 - 3 - 

 5. Representations and Warranties by MDCO. MDCO represents and warrants to the Company as
follows (it being understood that, as provided in Exhibit A, a condition to any exercise of this Warrant shall be that the following be updated as of the date of exercise): 

(a) This Warrant and the Shares issuable upon exercise of this Warrant are being acquired for its own account, for investment and not with a
view to, or for resale in connection with, any distribution or public offering thereof within the meaning of the Securities Act. Upon exercise of this Warrant, MDCO shall, if so requested by the Company, confirm in writing, in a form satisfactory to
the Company, that the securities issuable upon exercise of this Warrant are being acquired for investment and not with a view toward distribution or resale. 

(b) MDCO understands that the Warrant and the Shares have not been registered under the Securities Act by reason of their issuance in a
transaction exempt from the registration and prospectus delivery requirements of the Securities Act pursuant to Section 4(2) thereof, and that they must be held by MDCO indefinitely, and that MDCO must therefore bear the economic risk of
such investment indefinitely, unless a subsequent disposition thereof is registered under the Securities Act or is exempted from such registration. 

(c) MDCO has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of the
purchase of this Warrant and the Shares purchasable pursuant to this Warrant and of protecting its interests in connection therewith 
 (d)
MDCO is able to bear the economic risk of the purchase of the Shares purchasable pursuant to this Warrant. 
 (e) MDCO is an
“accredited investor,” as such term is defined under Rule 501 promulgated pursuant to the Securities Act. 
 6. Company
Operating Agreement; Transfer Restrictions. This Warrant (and the Common Shares purchasable hereunder) shall only be transferable to the same extent any Common Shares held by the Holder are transferable under the Company Operating Agreement, and
this Warrant (and the Common Shares purchasable hereunder) shall be subject to the same transfer restrictions applicable to the Common Shares under the Company Operating Agreement. The Common Shares acquired pursuant to exercise of this Warrant
shall be fully subject to all of the terms and conditions contained in the Operating Agreement, and the Holder hereby acknowledges that it has read and understands the terms and conditions contained therein. 

7. Rights of Members. MDCO shall not be entitled, as a Warrant holder, to vote or receive dividends or be deemed the holder of the
Shares or any other securities of the Company which may at any time be issuable on the exercise hereof for any purpose, nor shall anything contained herein be construed to confer upon MDCO any of the rights of a member of the Company or any right to
vote for the election of managers or upon any matter submitted to members at any meeting thereof, or to give or withhold consent to any limited liability company action, to receive notice of meetings, or to receive dividends or subscription rights
or otherwise until the Warrant shall have been exercised and the Shares purchasable upon the exercise hereof shall have been delivered, as provided herein. 

  
 - 4 - 

 8. Expiration or Termination of Warrant; Notice of Liquidation Event or IPO. This Warrant
shall expire and shall no longer be exercisable upon the Expiration Date. If the Company proposes at any time to effect (a) a Liquidation Event or (b) an IPO, the Company shall give MDCO at least ten (10) days prior written notice of
the date when the same will take place (and, in the case of a Liquidation Event, specifying the date on which Members will be entitled to exchange their shares for the securities or other property deliverable upon the occurrence of such event). In
the event of an Liquidation Event, as an alternative to providing notice to MDCO, the Company shall have the right to terminate this Warrant in exchange for the payment to MDCO of consideration in an aggregate amount equal to the excess of the fair
market value (as reasonably determined by the Company’s Board of Managers) of the Shares over the aggregate Exercise Price thereof (the form of such consideration to be in the same form received by members for their Common Shares). 

9. Notices. All notices and other communications required or permitted hereunder shall be in writing, shall be effective when given as
set forth in the Securities Purchase Agreement. 
 10. Miscellaneous. This Warrant and all actions arising out of or in connection
with this Warrant shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to the conflicts of law provisions of the State of Delaware or of any other state. This Warrant and any term hereof may be
changed, waived, discharged or terminated only by an instrument in writing signed by MDCO and the Company. The headings in this Warrant are for purposes of reference only, and shall not limit or otherwise affect any of the terms hereof. 

 

			
	GENO, LLC
		
	By:	 	 /s/ David H. Fine

	Name:	 	David Fine
	Title:	 	President

  

			
	ACKNOWLEDGED BY:
	
	THE MEDICINES COMPANY
		
	By:	 	 /s/ Glenn Sblendorio

	Name:	 	Glenn Sblendorio
	Title:	 	Executive Vice President and CFO

  
 - 5 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}]]